Highly effective peginterferon alpha-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
- Authors
- Yang, Suh Yoon; Lee, Hyun Woong; Lee, Youn Jae; Park, Sung Jae; Yoo, Ki Young; Kim, Hyung Joon
- Issue Date
- Jun-2015
- Publisher
- KOREAN ASSOC STUDY LIVER
- Keywords
- Chronic hepatitis C; Hemophilia; Peginterferon; Ribavirin
- Citation
- CLINICAL AND MOLECULAR HEPATOLOGY, v.21, no.2, pp 125 - 130
- Pages
- 6
- Journal Title
- CLINICAL AND MOLECULAR HEPATOLOGY
- Volume
- 21
- Number
- 2
- Start Page
- 125
- End Page
- 130
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/9478
- DOI
- 10.3350/cmh.2015.21.2.125
- ISSN
- 2287-2728
2287-285X
- Abstract
- Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the safety and efficacy of combination therapy with peginterferon alpha-2a plus ribavirin for CHC in hemophilia. Methods: Patients (n=115) were enrolled between March 2007 and December 2008. Seventy-seven patients were genotype 1 or 6, and 38 patients were genotype 2 or 3. We evaluated rapid virologic responses (RVRs), early virologic response (EVRs), end-of-treatment response (ETRs), sustained virologic response (SVRs), and relapses. Safety evaluations included adverse events and laboratory tests. Results: Eleven patients were excluded from the study because they had been treated previously. Among the remaining 104 treatment-naive patients, RVR was achieved in 64 (60.6%), ETR was achieved in 95 (91.3%), and SVR was achieved in 89 (85.6%). Relapse occurred in eight patients (8.9%). Common adverse events were hair loss (56.7%) and headache (51.0%). Common hematologic adverse events were neutropenia (22.1%), anemia (27.9%), and thrombocytopenia (3.8%). However, there were no serious adverse events such as bleeding. RVR was the only predictor of SVR in multivariate analysis. Conclusions: Peginterferon alpha-2a plus ribavirin combination treatment produced a favorable response rate in CHC patients with hemophilia without serious adverse events.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.